Advances in therapy
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.
Hermann Einsele, Philippe Moreau, Nizar Bahlis, Manisha Bhutani, Laure Vincent, Lionel Karlin, Aurore Perrot, Hartmut Goldschmidt, Niels W C J van de Donk, Enrique M Ocio, Joaquín Martínez López, Paula Rodríguez-Otero, Dominik Dytfeld, Andrzej Jakubowiak, Carolina Schinke
Published: 202510.1007/s12325-025-03409-y
Abstract
INTRODUCTION: Talquetamab, a bispecific antibody targeting GPRC5D, is approved for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) based on results from MonumenTAL-1. We report updated indirect comparisons of talquetamab vs. re…
Preview only. Read the full abstract at the source